Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ginsenoside F1 in preparation of anti-atherosclerosis medicament

A technology for atherosclerosis and ginsenosides, applied in the field of medicine, can solve the problems of complex formation mechanism and unsatisfactory curative effect.

Inactive Publication Date: 2014-05-28
INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The formation mechanism of atherosclerosis (AS) is complex. Modern theories believe that atherosclerosis is a process of chronic inflammation mainly caused by oxidized lipids. drugs, but the curative effect is not satisfactory, and there is an urgent need for a large number of new drug development research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside F1 in preparation of anti-atherosclerosis medicament
  • Application of ginsenoside F1 in preparation of anti-atherosclerosis medicament
  • Application of ginsenoside F1 in preparation of anti-atherosclerosis medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: The effect of ginsenoside F1 on the formation of atherosclerotic plaques in the aortic arch of ApoE- / - mice.

[0018] Apolipoprotein E gene knockout ApoE- / - mice were induced with high-fat diet for 8 weeks to establish atherosclerotic plaque model, C57 mice were used as blank control, and the administration group was given 50 mg / kg ginsenoside F1 every day. After the experiment, they were sacrificed by dislocation, fixed by perfusion with 4% paraformaldehyde, and the aortic arch and nearby tissues were collected for OTC embedding and stored in a -80°C refrigerator. Frozen sections were kept from the time when three complete aortic valves appeared, 80 pieces were reserved for each, and every other 4 pieces were picked for staining (16 pieces in total) and stained with 0.5% oil red, recovered with hematoxylin, and washed with water to return to blue. The slides were sealed with neutral gum, and the Olympus upright microscope Image pro plus6.0 software was taken...

Embodiment 2

[0020] Example 2: Effect of Ginsenoside F1 on Inflammatory Response in ApoE- / - Mice

[0021] The bioluminescent MPO inflammatory probe was used as an indicator, and the probe was injected intraperitoneally for 15 minutes to detect the generation of inflammatory mediators in the mouse body using the Jinguozhen spectrum small animal live imaging. The excitation light wavelength was 750λm, and the total luminous intensity was measured. The results are shown in figure 2 .

[0022] The luminescence intensity of the ApoE- / - model group was 2.9 times that of the C57 blank group, while the F1 administration group could reduce the luminescence intensity to 1.5 times that of the blank group.

Embodiment 3

[0023] Example 3: Effect of ginsenoside F1 on LOX-1 and TLR-4 receptors in the aortic arch intima of ApoE- / - mice

[0024] Frozen sections of ApoE- / - mouse aortic arch were placed at room temperature for 30 minutes, washed with water, equilibrated with PBS for 10 minutes, blocked with goat serum for 1 hour, incubated with primary antibody for 1 hour at room temperature, washed 3 times with PBS for 5 minutes each, and incubated with secondary antibody with FITC at room temperature in the dark. After 1 hour, wash with PBS for 3 times, each time for 5 minutes, seal the slides with DAPI-containing anti-fluorescence quenching mounting medium, observe quickly, and take photos with Olympus fluorescence inverted microscope at 100 times magnification. The results are shown in image 3 and 4 .

[0025] LOX-1 and TLR-4 were highly expressed on the intima of the aortic arch in the model group, and the expression of these two receptors could be significantly reduced in the F1 group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel application of a ginsenoside F1 medicament and in particular relates to application of the ginsenoside F1 in preparation of medicaments for preventing and treating atherosclerosis and coronary atherosclerotic heart disease.

Description

technical field [0001] The present invention relates to the application of a medicinal active ingredient in the preparation of medicine, in particular to the application of ginsenoside F1 in the prevention and treatment of atherosclerosis and coronary atherosclerotic heart disease (coronary heart disease) as the primary pathogenic factor. The new application belongs to the field of medical technology. Background technique [0002] Coronary artery heart disease (CHD, referred to as coronary heart disease), as the most common ischemic heart disease, has become a major disease that threatens the safety of human life. Coronary heart disease is the result of various coronary artery diseases, among which the pathological basis is vascular stenosis caused by coronary atherosclerosis, which accounts for the vast majority of coronary heart diseases. The formation mechanism of atherosclerosis (AS) is complex. Modern theories believe that atherosclerosis is a process of chronic inflam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7032A61P9/10
Inventor 孙晓波孙桂波秦蒙
Owner INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com